<DOC>
	<DOCNO>NCT01812746</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety BIND-014 patient metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>A Phase 2 Study Determine Safety Efficacy BIND-014 ( Docetaxel Nanoparticles Injectable Suspension ) , Administered Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Metastatic disease progress despite castrate level testosterone Prostate cancer progression document PSA Surgically medically castrate , testosterone level &lt; 50 ng/dL Previous antiandrogen therapy progression withdrawal ECOG performance status 0 1 Adequate organ function Prior radiation therapy allow &lt; 25 % bone marrow Prior hormonal therapy allow Patient compliance geographic proximity allow adequate followup . Patients reproductive potential must use contraceptive method Signed informed consent patient Active infection Any chronic medical condition require high dos corticosteroid Pathological finding consistent small cell carcinoma prostate Brain metastasis Prior cytotoxic chemotherapy biologic therapy treatment CRPC Radiation therapy treatment primary tumor within 6 week Radionuclide therapy treatment metastatic CRPC Prior systemic treatment azole drug Prior flutamide treatment within 4 week Prior bicalutamide nilutamide within 6 week Congenital long QT syndrome , congestive heart failure , bradyarrhythmia Administration investigational therapeutic within 2 week Second primary malignancy Presence clinically detectable thirdspace fluid collection History severe hypersensitivity reaction polysorbate 80 Peripheral neuropathy study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>